Loading
A phase 2 trial of Abenacianine run by Vergent Bioscience, Inc., completed.
Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung. is a phase 2 interventional study registered as NCT06145048 by Vergent Bioscience, Inc., with 89 participants enrolled, started 2023-10-05. Conditions recorded: Lung Cancer and Lung Metastases. Interventions recorded: VGT-309.
Shares Abenacianine, Vergent Bioscience, Lung cancer (all types) and the tag pipeline.
Shares Abenacianine, Vergent Bioscience and the tag pipeline.
Shares Abenacianine, Vergent Bioscience and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/